申请人:The DuPont Merck Pharmaceutical Company
公开号:US05760029A1
公开(公告)日:1998-06-02
This invention relates to novel heterocycles, including (S)-2-phenylsulfonylamino-3-\x9b\x9b\x9b8-(2-pyridinylaminomethyl)-!-1-oxa-2-azaspi ro-\x9b4,5!-dec-2-en-3-yl!carbonylamino! propionic acid, which are useful as antagonists of the .alpha..sub.v .beta..sub.3 integrin and related cell surface adhesive protein receptors, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of cell adhesion, the treatment of angiogenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, thrombosis, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis.
本发明涉及新型杂环,包括(S)-2-苯基磺酰氨基-3-[8-(2-吡啶基氨甲基)-1-氧杂-2-氮杂螺[4,5]癸-2-烯-3-基]甲酰氨基丙酸等,这些化合物可用作αvβ3整合素和相关细胞表面粘附蛋白受体的拮抗剂,制备这些化合物的方法,以及使用这些化合物的方法,单独或与其他治疗剂联合使用,用于抑制细胞黏附、治疗血管新生障碍、炎症、骨降解、癌症转移、糖尿病视网膜病变、血栓形成、再狭窄、黄斑变性和其他通过细胞黏附、细胞迁移和/或血管生成介导的疾病。